Centice Corp

Centice Corp (Delaware inc 2003, NC registration 2003, Morrisville NC HQ near Research Triangle Park) develops Raman spectroscopy sensors for drug identification and verification. Founded on Duke University patented computational sensor tech. Products: Mobile Field Lab 3000, PASS Rx pharmaceutical authentication. Raised 39.5M total. Investors: Aurora Funds, Novak Biddle Venture Partners, Fulcrum Equity Partners, S-Group Direct Investments, QWave Capital. Series D (2012): 8M led by Aurora and including QWave. Has SBIR government grants. Board directors per SEC Form D: Frank Creer, Serguei Kouzmine (QWave), Vladimir Yakushev, Aidar Gabidullin. CEO: Prasant Potuluri (previously Matt Albert of Aurora Funds served as CEO from 2010). Legitimate spectroscopy technology company, not a shell, but funded in part by QWave Capital whose managing partner is a Tambovskaya mafia economics expert.

Centice is a real operating company with actual products, government contracts (SBIR), and legitimate investors (Aurora Funds, Novak Biddle). However, its connection to QWave Capital brought both Kouzmine (board seat) and Creer (board seat) to the same corporate governance table. The technology (Raman spectroscopy for drug identification) has obvious law enforcement/intelligence applications. The company had registrations in Delaware, NC, CT, and FL.

Dual sanctioned oligarch capital streams: S-Group (Mordashov) invested from 2009-2013 and QWave (Kouzmine) invested USD 7M in 2013

Centice Corp (Morrisville NC, CIK 0001415617) received capital from two independent Russian oligarch-connected sources: (1) S-Group Capital Management (Mordashov's vehicle) co-led USD 4M bridge round in 2009, followed by debt round Jul 2012 and Series E USD 9.86M in Mar 2013. S-Group appointed Yakushev and likely Gabidullin to board. (2) QWave Capital (Kouzmine's vehicle) invested USD 7M in Jun 2013 as part of initial round alongside Nano-Meta Technologies and Clifton. Kouzmine became Centice board member. The company also had investors including Aurora Funds, Novak Biddle Venture Partners, Innovation Ventures. Total identified Reg D filings span 2007-2014 with 30 Form D/D-A filings. Both Mordashov (sanctioned by EU/US/UK) and Kouzmine (connected to Tambovskaya mafia via his DFJ/QWave network) funneled capital into this small NC spectroscopy company that sold narcotics identification systems to law enforcement.

Centice Corp raised multiple private equity/debt rounds 2008-2014 totaling over $15M per Form D filings

Centice Corp (CIK 1415617) filed Form D series: 2009 debt round $4M (6 investors); 2010-03 equity round $2.5M offered/$618K sold (3 investors); 2011-05 equity $2.5M offered/$600K sold; 2011-10 equity $2.5M offered/$865K sold; 2012-02 equity $2.5M offered/$865K sold; 2012-08 equity $2.5M offered/$1M sold; 2013-03 equity offering (total raised by 2013: ~$9.83M); 2013-10 equity $1.5M/$115K sold; 2014 amendment. All investors were accredited, no sales commissions paid. No GLEIF LEI record found for Centice, suggesting it never reached public market status.

7 of 9 Centice patents transferred to Readsboro International Corporation on 2016-08-11 via STRICT FORECLOSURE RESULTING FROM PROMISSORY NOTE DEFAULT (Reel/Frame 41190/466). Supplement filed 2017-02-07 (41650/55). Patents transferred: 7218395, 7720694, 7830507, 8331678, 8417539, 8417540, 8731959. Two patents (7379181, 8144320) were NOT foreclosed.

Complete Centice patent extraction timeline: S-Group investment (2009) → Oscrivia/Fulcrum security interest (2012) → Readsboro foreclosure (2016) → ASB International Services (2020)

The Centice Corp patent extraction followed a 4-stage pipeline confirmed via USPTO assignment records: (1) S-Group Direct Investments co-led bridge financing and placed partner Gabidullin on the board at c/o Oscrivia address (2009); (2) Oscrivia + Fulcrum Financial Partners took joint security interest on all 9 patents (Feb 2012, released Feb 2013); (3) Ghost entity Readsboro International Corporation (Cyprus) foreclosed on 7 patents via strict foreclosure from promissory note default (Aug 2016); (4) Readsboro transferred to ASB International Services Ltd (Cyprus, HE385193, nominee-directed by DGH Services Ltd) in Dec 2020. Two patents (7379181, 8144320) were not foreclosed. A prior security interest by Vogen Funding LP on patent 7379181 (2008-2012) was released just before Oscrivia/Fulcrum took theirs.

Centice Corp (CIK 1415617) formerly named Optopo Inc; NC-based biotech Delaware incorporated

Centice Corp CIK 1415617 is a Delaware-incorporated corporation with NC operations address at 215 Southport Drive, Suite 1000, Morrisville NC 27560, phone 919-653-0424. Industry: Biotechnology (early filings) / Other Technology (later filings). Form D series from 2008-2014 documenting multiple equity/debt private placements. Previous name: Optopo Inc. Multiple rounds of fundraising documented; total amount sold across all forms approximately $15M+ across 2008-2014 period.

Centice Corp held 9 granted US patents covering Raman spectroscopy and pharmaceutical identification technology, all assigned from inventors (David Brady, Prasant Potuluri, et al.) 2005-2010. Patent numbers: 7218395, 7379181, 7720694, 7830507, 8144320, 8331678, 8417539, 8417540, 8731959.

Readsboro International Corporation transferred all 7 Centice patents to ASB International Services Ltd (Cyprus, HE385193) on 2020-12-29 (recorded 2021-03-18, Reel/Frame 55638/474). ASB is a Cyprus company at Prevezis 12, Nicosia, directed by nominee company DGH Services Ltd (HE369802). ASB status is 'Reminder Letter Sent' indicating non-compliance.